Macrophage-Based Therapies for Atherosclerosis Management

Peng, Renyi; Ji, Hao; Jin, Libo; Lin, Sue; Huang, Yijiang; Xu, Ke; Yang, Qinsi; Sun, Da; Wu, Wei

doi:10.1155/2020/8131754

Cited by 39 publications

(28 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After scavenger receptors initially interact with free cholesterol, cholesterol transporters facilitate uptake of free cholesterol by macrophages; mitochondria then use cholesterol to generate ATP through cholesterol metabolism enzymes [ 41 ]. Importantly, cholesterol transporters can also facilitate excretion of excess cholesterol from cells [ 42 ]. The balance between cholesterol uptake and release therefore affects macrophage function.…”

Section: Discussionmentioning

confidence: 99%

Oxidized LDL Disrupts Metabolism and Inhibits Macrophage Survival by Activating a miR-9/Drp1/Mitochondrial Fission Signaling Pathway

Xin

Zhang

et al. 2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Mitochondrial dysfunction is associated with macrophage damage, but the role of mitochondrial fission in macrophage cholesterol metabolism is not fully understood. In this study, we explored the influences of miR-9 and mitochondrial fission on macrophage viability and cholesterol metabolism. Macrophages were incubated with oxidized low-density lipoprotein (ox-LDL) in vitro, after which mitochondrial fission, cell viability, and cholesterol metabolism were examined using qPCR, ELISAs, and immunofluorescence. ox-LDL treatment significantly increased Drp1-associated mitochondrial fission. Transfection of Drp1 siRNA significantly reduced cell death, attenuated oxidative stress, and inhibited inflammatory responses in ox-LDL-treated macrophages. Interestingly, inhibition of Drp1-related mitochondrial fission also improved cholesterol metabolism by balancing the transcription of cholesterol influx/efflux enzymes. We also found that miR-9 was downregulated in ox-LDL-treated macrophages, and administration of a miR-9 mimic decreased Drp1 transcription and mitochondrial fission, as well as its effects. These results indicate that signaling via the novel miR-9/Drp1/mitochondrial fission axis is a key determinant of macrophage viability and cholesterol metabolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Oxidized LDL Disrupts Metabolism and Inhibits Macrophage Survival by Activating a miR-9/Drp1/Mitochondrial Fission Signaling Pathway

Xin

Zhang

et al. 2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…Atherosclerosis refers to the pathophysiological conditions where the medium and large arteries are significantly affected due to spatial deposition of various materials such as lipoproteins (particularly cholesterol), immune cells (circulating monocytes), proinflammatory factors (i.e., macrophages and T-cells), degraded extracellular matrix components and necrotic products. Atherosclerosis is considered to be the primary cause of chronic CVDs, including coronary heart disease, cerebrovascular disease, and peripheral arterial disease [ 38 , 39 , 40 ]. Atherosclerosis is characterized by a series of physiological events, including endothelial dysfunction, inflammatory responses, cell proliferation, lipoprotein deposition, vascular remodeling, and finally, plaque formation [ 41 ].…”

Section: Nanotheranostics For Atherosclerosismentioning

confidence: 99%

“…The inflammation is due to the secretion of several proteases and tissue factors under macrophages’ influence. Hence, macrophage-targeted therapeutics are considered to be promising in minimizing the inflammatory responses and the degradation of atherosclerotic plaques [ 39 ]. The design and development of theranostic nanomaterials for the management of atherosclerosis depend upon several physiological markers.…”

Section: Nanotheranostics For Atherosclerosismentioning

confidence: 99%

Nanomaterials as Novel Cardiovascular Theranostics

et al. 2021

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a group of conditions associated with heart and blood vessels and are considered the leading cause of death globally. Coronary heart disease, atherosclerosis, myocardial infarction represents the CVDs. Since CVDs are associated with a series of pathophysiological conditions with an alarming mortality and morbidity rate, early diagnosis and appropriate therapeutic approaches are critical for saving patients’ lives. Conventionally, diagnostic tools are employed to detect disease conditions, whereas therapeutic drug candidates are administered to mitigate diseases. However, the advent of nanotechnological platforms has revolutionized the current understanding of pathophysiology and therapeutic measures. The concept of combinatorial therapy using both diagnosis and therapeutics through a single platform is known as theranostics. Nano-based theranostics are widely used in cancer detection and treatment, as evident from pre-clinical and clinical studies. Nanotheranostics have gained considerable attention for the efficient management of CVDs. The differential physicochemical properties of engineered nanoparticles have been exploited for early diagnosis and therapy of atherosclerosis, myocardial infarction and aneurysms. Herein, we provided the information on the evolution of nano-based theranostics to detect and treat CVDs such as atherosclerosis, myocardial infarction, and angiogenesis. The review also aims to provide novel avenues on how nanotherapeutics’ trending concept could transform our conventional diagnostic and therapeutic tools in the near future.

show abstract

“…Cardio/cerebrovascular disease (CVD) is one of the main reasons for the increase of global mortality and AS has been considered to be the main pathological basis for inducing cardio/cerebrovascular disease. 1 AS is a chronic inflammatory vascular disease 2 coming from the excessive and unregulated scavenger receptor-mediated internalization of oxidized low-density lipoprotein (oxLDL) in macrophages and their accumulation on the arterial wall to form lipid-rich plaques. 3 Currently, the main treatments of AS are drug treatment and surgical treatment.…”

Section: Introductionmentioning

confidence: 99%

The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis

Sha¹,

Dai²,

Song³

et al. 2021

IJN

View full text Add to dashboard Cite

Atherosclerosis (AS) as the leading cause of cardiovascular and cerebrovascular events has been paid much attention all the time. With the continuous development of modern medical drug treatment, surgical treatment, interventional treatment and other methods, the mortality rate of AS has shown a downward trend, while the morbidity rate is still increasing. Oral lipid-lowering or anti-inflammatory drugs are generally used for early AS, but the relatively low accumulation efficiency in lesions and the unavoidable side effects required researchers to develop more effective drug delivery approaches for the therapy of AS. Mesoporous silica nanoparticles as nanocarrier for drug delivery have received extensive attentions due to their flexible size, high specific surface area, controlled pore volume, high drug loading capacity and excellent biocompatibility. Series of good reviews about the mesoporous silica nanoparticles loaded drugs for cancer therapy have been well documented. However, their roles as nanocarrier for drug delivery to treat AS have few reports. In this review, the applications and challenges of mesoporous silica nanomaterials in the field of the diagnosis and therapy of AS have been summarized. The classification, synthesis, formation mechanism, surface modification and functionalization of mesoporous silica nanomaterials which were closely related to the theranostic effect of AS have also been included. Last but not the least, the future prospects’ suggestions of mesoporous silica nanomaterial-based drug delivery system for AS are also provided.

show abstract

Macrophage-Based Therapies for Atherosclerosis Management

Cited by 39 publications

References 105 publications

Oxidized LDL Disrupts Metabolism and Inhibits Macrophage Survival by Activating a miR-9/Drp1/Mitochondrial Fission Signaling Pathway

Oxidized LDL Disrupts Metabolism and Inhibits Macrophage Survival by Activating a miR-9/Drp1/Mitochondrial Fission Signaling Pathway

Nanomaterials as Novel Cardiovascular Theranostics

The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis

Contact Info

Product

Resources

About